Short answer
Oncology Institute, Inc. (TOI) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $161M (up 34.6% year over year) with net income of −$10M.
Q2 2026 key financials · XBRL
- Revenue
- $161M
- +34.6% YoY · +9.4% QoQ
- Net income
- −$10M
- +42.4% YoY · −292.8% QoQ
- Operating margin
- -2.9%
- EPS (diluted)
- −$0.08
- +42.9% YoY · −300.0% QoQ
Source: XBRL data from the Oncology Institute, Inc. (TOI) Q2 2026 10-Q on SEC EDGAR. USD.
Oncology Institute, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $161.282M, up 34.6% YoY from $119.802M
- Specialty Pharmacy revenue $98.608M, up 57.6% YoY, best-performing segment
- Clinical trials & other revenue $3.847M, up 187.5% YoY, fastest growth
- Operating margin (2.9%) vs (9.4%) YoY; net margin (6.1%) vs (14.2%)
- Cash $41.094M; six-month operating cash flow $9.725M vs $(15.190)M YoY
Risk Factors
- No risk-factors section provided in the submitted excerpt
- No newly added risk or material 10-K comparison disclosed
- No regulatory, legal, operational, competitive, market, or financial risk details available in the text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oncology Institute, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.